Tebideutorexant

Last updated

Tebideutorexant
JNJ-61393215.svg
Clinical data
Other namesJNJ-61393215; JNJ-3215
Routes of
administration 		Oral
Drug class Orexin receptor antagonist
Pharmacokinetic data
Elimination half-life 14–25 hours [1]
Identifiers
  • {(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl}-[3-fluoro-2-(pyrimidin-2-yl)phenyl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C23H16D2F4N4O2
Molar mass 460.428 g·mol−1
3D model (JSmol)
  • [2H]C1([2H])[C@H]2C[C@@H](Oc3ccc(C(F)(F)F)cn3)[C@H](C2)N1C(=O)c1cccc(F)c1-c1ncccn1
  • InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2
  • Key:HUKWIAXQBOHZIX-USKNZQBOSA-N

Tebideutorexant [2] (developmental code names JNJ-61393215, JNJ-3215) is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders. [3] [4] [5] [6] The drug was originated and developed by Janssen Pharmaceuticals. [3]

It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA). [4] [5] [6] Preliminary clinical findings suggest that tebideutorexant may have anti-panic effects in humans. [4] [5] The elimination half-life of tebideutorexant is 13.6 to 24.6 hours. [1]

As of June 2023, tebideutorexant is in phase 2 clinical trials for the treatment of major depressive disorder while no further development has been reported for treatment of panic disorder and other anxiety disorders. [3] In 2025, a phase 2a, double-blind, placebo-controlled trial in adults with major depressive disorder and anxious distress found that adjunctive tebideutorexant did not significantly improve depressive symptoms on the Hamilton Rating Scale for Depression or anxiety on the Hamilton Anxiety Rating Scale compared with placebo. [7]

See also

References

  1. 1 2 Brooks S, Zuiker R, Bleys C, Ziagkos D, Moyer J, van Nueten L, et al. (2023). "Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers". Journal of Psychopharmacology. 37 (6): 577–589. doi: 10.1177/02698811231167989 . hdl: 1887/3720682 . ISSN   0269-8811. PMID   37165642 . Retrieved 27 July 2025.
  2. ↑ PubChem. "Tebideutorexant". pubchem.ncbi.nlm.nih.gov. Retrieved 2024-08-15.
  3. 1 2 3 "JNJ 61393215 - AdisInsight".
  4. 1 2 3 Caldirola D, Alciati A, Cuniberti F, Perna G (2021). "Experimental Drugs for Panic Disorder: An Updated Systematic Review". Journal of Experimental Pharmacology. 13: 441–459. doi: 10.2147/JEP.S261403 . PMC   8055642 . PMID   33889031.
  5. 1 2 3 Jacobson LH, Hoyer D, de Lecea L (May 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". Journal of Internal Medicine. 291 (5): 533–556. doi:10.1111/joim.13406. PMID   35043499. S2CID   248119793.
  6. 1 2 Salvadore G, Bonaventure P, Shekhar A, Johnson PL, Lord B, Shireman BT, et al. (September 2020). "Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans". Translational Psychiatry. 10 (1) 308. doi:10.1038/s41398-020-00937-9. PMC   7477545 . PMID   32895369.
  7. ↑ Schmidt ME, Moyer JA, Kezic I, Zhou X, Samtani MN, Bleys C, et al. (June 2025). "Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a study". European Neuropsychopharmacology. 95: 14–23. doi:10.1016/j.euroneuro.2025.03.007. PMID   40215570.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.